Triglyceride-rich lipoproteins and atherosclerosis

Area of Science:

• Cardiovascular Medicine
• Lipid Metabolism
• Atherosclerosis Research

Background:

• Plasma triglyceride levels are increasingly recognized as a risk factor for coronary heart disease (CHD).
• Epidemiological studies consistently link elevated triglycerides with higher CHD incidence.
• The atherogenic potential of triglyceride-rich lipoproteins is supported by in vitro and in vivo data.

Purpose of the Study:

• To consolidate evidence supporting plasma triglycerides as a risk factor for coronary heart disease.
• To examine the impact of lowering triglyceride levels on CHD mortality.
• To investigate the role of triglyceride-rich lipoprotein remnants in atherogenesis.

Main Methods:

• Review of epidemiological data from major cohort studies (e.g., Framingham, Paris, Stockholm).
• Analysis of studies correlating triglyceride levels with CHD incidence and mortality.
• Examination of angiographic findings and in vitro/in vivo studies on lipoprotein particle atherogenicity.

Main Results:

• Elevated plasma triglyceride levels are associated with increased coronary heart disease incidence.
• Significant reductions in CHD mortality (36-60%) observed with effective triglyceride lowering.
• Stronger association between triglycerides and CHD noted in patients with lower total cholesterol or HDL-cholesterol.
• Evidence suggests triglyceride-rich lipoprotein remnants are cytotoxic and atherogenic.

Conclusions:

• Plasma triglyceride levels are a confirmed risk factor for coronary heart disease.
• Therapeutic strategies aimed at lowering triglycerides can significantly reduce CHD mortality.
• Understanding the atherogenic mechanisms of triglyceride-rich lipoproteins is crucial for cardiovascular risk management.